DOI QR코드

DOI QR Code

Phase II Study on Dose Escalating Schedule of Paclitaxel Concurrent with Radiotherapy in Treating Patients with Locally Advanced Non-small Cell Lung Cancer

  • Cui, Lin ;
  • Liu, Xing-Xiang ;
  • Jiang, Yong ;
  • Liu, Jian-Jun ;
  • Zhou, Xiang-Rong ;
  • He, Xue-Jun ;
  • Chen, Jue ;
  • Huang, Xin-En
  • Published : 2014.02.28

Abstract

Objective: To evaluate clinical efficacy of a dose escalating schedule of paclitaxel concurrent with radiotherapy in treating patients with locally advanced non-small cell lung (NSCLC). Methods: Patients with locally advanced NSCLC were treated with conventional fractionated radiotherapy or three dimensional conformal radiotherapy (3 DCRT), concurrently with a dose escalating schedule of paclitaxel. All patients were divided into three groups, A with paclitaxel $30mg/m^2$, B with paclitaxel $60mg/m^2$ and C with paclitaxel $90mg/m^2$. Paclitaxel was repeated every week for a total of 4 or 6 weeks. Results: Among 109 patients, response rates were 68.8%, 71.1% and 71.8% (p>0.05) for group A (n=32), B (n=38), and C (n=39) respectively. Accordingly, disease control rates were 81.3%, 81.6% and 82.1% (p>0.05). Progression-free survival time was $8.0{\pm}5.0$ months, $11.6{\pm}6.1$ months, and $14.8{\pm}7.9$ months (p<0.05), respectively. Overall survival time was $15.4{\pm}7.6$ months, $18.2{\pm}8.0$ months, and $22.0{\pm}7.6$ months (p<0.05), one-year survival rates were 62.5%, 73.1% and 90.0% (p>0.05) and two-year survival rates were 31.3%, 38.5% and 50.0% (p<0.05). Main side-effects were bone marrow suppression, radiation related esophagitis and gastrointestinal reaction. Conclusion: In treating patients with NSCLC, concurrent chemoradiotherapy with paclitaxel improves early response compared with conventional fractionated radiotherapy or 3 DCRT. The survival rate was improved with the addition of paclitaxel, but there was an increase in adverse reactions when the dose of paclitaxel was increased.

Keywords

Non-small cell lung cancer;concurrent chemoradiotherapy;paclitaxel;prognosis

References

  1. Yin HT, Tian QZ, Guan L, et al (2013). In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac J Cancer Prev, 14, 1703-6. https://doi.org/10.7314/APJCP.2013.14.3.1703
  2. Vokes E E, Herndon J E 2nd, Crawford J, et al (2002). Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant Chemoradiotherapy for stage M b non-small cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol, 20, 4191-8. https://doi.org/10.1200/JCO.2002.03.054
  3. Wang X, Wang , Lu J, et al (2006). Concurrent paclitaxel or/and carboplatin with radiotherapy for stageIIInon-small cell lung cancer. Chin J Rad Oncol, 15, 270-4.
  4. Wu Y, Liao M, Jiang G, et al (2002). Consensus on the diagnosis and treatment of local advanced non-small cell lung cancer. Chin J Oncol, 24, 576.
  5. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/ docetaxel combined with a platinum in the treatment of advanced non-small cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pac J Cancer Prev, 10, 1147-50.
  6. Zhou X, Cui L, Liu J (2009). Sequential and Concurrent Chemo- Radiotherapy for Middle and Advanced Stage Non-Small Cell Lung Cancer. J Basic Clin Oncol, 22, 132-3.
  7. Lu J, Wang L, Zhou Z, et al (2004). Phase II study on concomitant paclitaxel and radiotherapy for loc ally advanced non-small cell lung cancer[J]. Chin J Rad Oncol, 13, 89-92.
  8. Lara PN Jr, Goldberg Z, Davies A, et a1 (2002). Concurrent chemoradiation strategies in the management of unresectable stage III non-small-cell lung cancer. Clin Lung Cancer, 3, 42-8. https://doi.org/10.3816/CLC.2002.s.013
  9. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. https://doi.org/10.7314/APJCP.2013.14.4.2663
  10. Lu B, Ouyang W, Yi F, et al (2004). Concurrent chemotherapy and radiotherapy for advanced non-small-cell lung cancer. Chin J Rad Oncol, 13, 177-9.
  11. Lu YY, Huang XE, Cao J, et al (2013). Phase II study on Javanica oil emulsion injection ($Yadanzi^{(R)}$) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 4791-4. https://doi.org/10.7314/APJCP.2013.14.8.4791
  12. Ourari-Dhahri B, Ben Slima H, Ben Amar J, et al (2012). Management of non small cell lung cancer. Tunis Med, 90, 847-51.
  13. Salama JK, Vokes EE (2013). New radiotherapy and Chemoradiotherapy approaches for non-small-cell lung cancer. J Clin Oncol, 31, 1029-38. https://doi.org/10.1200/JCO.2012.44.5064
  14. Sculier JP (2013). Nonsmall cell lung cancer. Eur Respir Rev, 22, 33-6. https://doi.org/10.1183/09059180.00007012
  15. Solomon B, Ball DL, Richardson G, et al (2003). Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. Lung Cancer, 41, 353-61. https://doi.org/10.1016/S0169-5002(03)00235-6
  16. Trotti A, Byhardt R, Stetz J, et al (2000). Common toxicity criteria:version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on chemotherapy. Int J Radiat Oncol Biol Phys, 47, 13-47. https://doi.org/10.1016/S0360-3016(99)00559-3
  17. Curran WJ Jr, Paulus R, Langer CJ, et al (2011). Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst, 103, 1452-60. https://doi.org/10.1093/jnci/djr325
  18. Chen LK, Liang Y, Yang QY, et al (2012). Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients. Asian Pac J Cancer Prev, 13, 1863-7. https://doi.org/10.7314/APJCP.2012.13.5.1863
  19. Chen Y, Pandya K, Keng PP, et al (2001). Schedule-dependent pulsed paclitaxel radio-sensitization for thoracic malignancy. Am J Clin Oncol, 24, 432-7. https://doi.org/10.1097/00000421-200110000-00004
  20. Cufer T, Ovcaricek T, O'Brien ME (2013). Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer, 49, 1216-25. https://doi.org/10.1016/j.ejca.2012.11.021
  21. Demirci E1, Daloglu F, Gundogdu C, et al (2013). Incidence and clinicopathologic features of primary lung cancer: a North-Eastern Anatolia region study in Turkey (2006-2012). Asian Pac J Cancer Prev, 14, 1989-93. https://doi.org/10.7314/APJCP.2013.14.3.1989
  22. Field JK, Oudkerk M, Pedersen JH, et al (2013). Prospects for population screening and diagnosis of lung cancer. Lancet, 382, 732-41. https://doi.org/10.1016/S0140-6736(13)61614-1
  23. Fournel P, Robinet G, Thomas P, et al (2005). Randomized phase III trial of sequential Chemoradiotherapy compared with concurrent Chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienned Oncologie Thoracique-Groupe Francais de Pneumo- Cancerologie NPC 95-01 Study. J Clin Oncol, 23, 5910-7. https://doi.org/10.1200/JCO.2005.03.070
  24. Jemal A, Siegel R, Ward E, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. https://doi.org/10.3322/caac.20073
  25. Jiang Y, Cui L, Wu X, et al (2012). Radiosensitizing Effect of Weekly-dose Paclitaxel on Locally Advanced Esophageal Carcinoma. J Basic Clin Oncol, 6, 489-92.
  26. Al-Hashimi MM, Wang XJ (2014). Trend analysis of lung cancer incidence rates in ninawa province, iraq, from 2000 to 2010 - decrease and recent stability. Asian Pac J Cancer Prev, 15, 385-90. https://doi.org/10.7314/APJCP.2014.15.1.385
  27. Andoh H, McNulty NJ, Lewis PJ (2013). Improving accuracy in reporting CT scans of oncology patients: assessing the effect of education and feedback interventions on the application of the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Acad Radiol, 20, 351-7. https://doi.org/10.1016/j.acra.2012.12.002
  28. Byhardt RW, Scott C, Sause WT, Emami B, et al (1998). Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung. Int J Radiat Oncol Biol Phys, 42, 469-78. https://doi.org/10.1016/S0360-3016(98)00251-X

Cited by

  1. Clinical Investigation of Efficacy of Albumin Bound Paclitaxel plus Platinum Compounds as First-line Chemotherapy for Stage III/IV Squamous Non-small Cell Lung Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7453
  2. v6 and E-cadherin and Lymphatic Metastasis in Non-small Cell Lung Cancer vol.15, pp.5, 2014, https://doi.org/10.7314/APJCP.2014.15.5.2221
  3. Targeted Efficacy of Dihydroartemisinin for Translationally Controlled Protein Expression in a Lung Cancer Model vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2511
  4. Analysis of CEA Expression and EGFR Mutation Status in Non-small Cell Lung Cancers vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3451
  5. Anti-Proliferation Effects and Molecular Mechanisms of Action of Tetramethypyrazine on Human SGC-7901 Gastric Carcinoma Cells vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3581
  6. Clinical Study on Safety and Efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection Manufactured in China) for Chinese Undergoing Chemotherapy vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.299
  7. A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4797
  8. Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6765
  9. Irinotecan as a Second-line Chemotherapy for Small Cell Lung Cancer: a Systemic Analysis vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1993
  10. Analysis on Early Detection of Lung Cancer by PET/CT Scan vol.16, pp.6, 2015, https://doi.org/10.7314/APJCP.2015.16.6.2215
  11. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3189
  12. Organ-sparing Surgery in Treating Patients with Liposarcoma of the Spermatic Cord: Institutional Experience and Pooled Analysis vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3419
  13. Radioactive Seed Implantation and Lobaplatin Chemotherapy Are Safe and Effective in Treating Patients with Advanced Lung Cancer vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4003
  14. Clinical Application of Recombinant Human Endostatin in Postoperative Early Complementary Therapy on Patients with Non-small Cell Lung Cancer in Chinese Mainland vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.4013
  15. Targeting cancer with sesterterpenoids: the new potential antitumor drugs vol.69, pp.3, 2015, https://doi.org/10.1007/s11418-015-0911-y
  16. Safety and Efficacy of a Mouth-Rinse with Granulocyte Colony Stimulating Factor in Patients with Chemotherapy-Induced Oral Mucositis vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.413
  17. A Clinical Study on Juheli (Recombinant Human Interleukin - 11) in the Second Prevention of Chemotherapy Induced Thrombocytopenia vol.17, pp.2, 2016, https://doi.org/10.7314/APJCP.2016.17.2.485
  18. The safety and clinical efficacy of recombinant human granulocyte colony stimulating factor injection for colon cancer patients undergoing chemotherapy vol.63, pp.12, 2017, https://doi.org/10.1590/1806-9282.63.12.1061